Jury awards Centocor $1.7B in patent case against Abbott - Minneapolis / St. Paul Business Journal:

azajir.wordpress.com
An Abbott spokesman said the companywill Horsham, Pa.-based Centocor, a division of (NYSE:JNJ), maked the blockbuster rheumatoid arthritis treatment Remicade, and had sued Abbot t over Abbott’s arthritis drug, Humira. Both are so-calledc anti-TNF arthritis treatments. Horsham, Pa.-based Centocor said it is the exclusivew licensee of the whichis co-owned by . Centocorr President Kim Taylorsaid “the jury recognizede our valuable intellectual property, findingg our patent both valid and We will continue to assert intellectual property rightds for our immunology therapies, as they offed significant advances in treatment for patients with a numbee of immune mediated inflammatory diseases.
” Abbotty spokesman Scott E. Stoffel said, “We are disappointedr in this verdict, and we are confident in the merits of our case and that we will prevaiklon appeal. “The evidence clearl established that Humira was the first ofits kind, fully-human anti-TNF antibody medicine,” Stoffelp said. “JNJ’s anti-TNF antibody Remicade, is partially made from mouswe DNA. JNJ did not launch a fully-human product until April 2009. In fact, only when Humirw was nearing its approval in 2002 did JNJ amend the patentt at issue in this litigation to claimm that it haddiscovered fully-human antibodiew in 1994.
JNJ acknowledged at trial that it did not stargt working ona fully-human antibody untikl 1997 — two yeards after Abbott discovered Humira and one year after Abbott filed its patent applications for Humira.”